Oramed Pharmaceuticals (XTAE:ORMP) EBIT per Share : ₪0.90 (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Oramed Pharmaceuticals EBIT per Share?

Oramed Pharmaceuticals's EBIT per Share for the three months ended in Mar. 2024 was ₪0.19. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₪0.90.

During the past 3 years, the average EBIT per Share Growth Rate was 12.10% per year. During the past 5 years, the average EBIT per Share Growth Rate was 8.70% per year. During the past 10 years, the average EBIT per Share Growth Rate was 0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Oramed Pharmaceuticals's EBIT per Share or its related term are showing as below:

XTAE:ORMP' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -183.7 Med: -4.7 Max: 12.1
Current: 12.1

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Oramed Pharmaceuticals was 12.10% per year. The lowest was -183.70% per year. And the median was -4.70% per year.

XTAE:ORMP's 3-Year EBIT Growth Rate is ranked better than
60.77% of 1305 companies
in the Biotechnology industry
Industry Median: 3.6 vs XTAE:ORMP: 12.10

Oramed Pharmaceuticals's EBIT for the three months ended in Mar. 2024 was ₪7.78 Mil.

Oramed Pharmaceuticals EBIT per Share Historical Data

The historical data trend for Oramed Pharmaceuticals's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oramed Pharmaceuticals EBIT per Share Chart

Oramed Pharmaceuticals Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-3.07

-2.10

-3.11

-3.53

0.64

Oramed Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.33	-0.35	-0.22	1.28	0.19

Oramed Pharmaceuticals EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Oramed Pharmaceuticals's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	26.072	/	40.567
=	0.64

Oramed Pharmaceuticals's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	7.78	/	41.564
=	0.19

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.90

Oramed Pharmaceuticals (XTAE:ORMP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Oramed Pharmaceuticals EBIT per Share Related Terms

Thank you for viewing the detailed overview of Oramed Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Oramed Pharmaceuticals (XTAE:ORMP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oramed Pharmaceuticals Inc (XTAE:ORMP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

ORMP:USA OJU1:Germany

Address

1185 Avenue of the Americas, Third Floor, New York, NY, USA, 10036

Website

https://www.oramed.com

Oramed Pharmaceuticals Inc is a pharmaceutical company which is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The ORMD-0801 is a proprietary product which is an orally ingestible insulin capsule for the treatment of diabetes. Its other product includes Oral Glucagon-like peptide-1 which is an incretin hormone, a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas.